Treatment for Scleroderma (Systemic Sclerosis): Options, Medications & Outlook
Evidence-based Scleroderma (Systemic Sclerosis) treatment: first-line medications, monitoring targets, escalation criteria, and long-term clinical outlook.
Updated March 27, 2026
Treatment for Scleroderma (Systemic Sclerosis) focuses on achieving remission or low disease activity, preventing structural damage, and maintaining functional capacity. Scleroderma is a chronic autoimmune disease causing skin hardening, fibrosis of internal organs (lungs, kidneys, GI tract), and vascular abnormalities. Raynaud's phenomenon is often an early manifestation; there is no cure.
Clinical Context
The primary approach involves NSAIDs, DMARDs (methotrexate first-line in RA), biologic agents (anti-TNF, anti-IL-6, JAK inhibitors), or hydroxychloroquine for SLE. Monitoring typically includes disease activity scores (DAS28, BASDAI), FBC and LFTs for DMARD toxicity, and joint imaging. Treatment intensity is tailored to disease severity, patient comorbidities, and response. Guideline-directed therapy reduces the risk of complications, hospitalisation, and disease progression.
Clinical Pathway
Scleroderma (Systemic Sclerosis) — Full Condition GuideCondition HubScleroderma (Systemic Sclerosis) — Treatment PathwaysTreatmentScleroderma (Systemic Sclerosis) — Prognosis & OutlookPrognosisScleroderma (Systemic Sclerosis) — Differential DiagnosisDifferentialRheumatoid Arthritis vs. Scleroderma (Systemic Sclerosis) — Comparisonvs.Frequently Asked Questions
Treatment for Scleroderma (Systemic Sclerosis): Options, Medications & Outlook?+
Treatment for Scleroderma (Systemic Sclerosis) focuses on achieving remission or low disease activity, preventing structural damage, and maintaining functional capacity. Scleroderma is a chronic autoimmune disease causing skin hardening, fibrosis of internal organs (lungs, kidneys, GI tract), and vascular abnormalities. Raynaud's phenomenon is often an early manifestation; there is no cure.
What is the first-line treatment for Scleroderma (Systemic Sclerosis)?+
First-line treatment typically involves NSAIDs, DMARDs (methotrexate first-line in RA), biologic agents (anti-TNF, anti-IL-6, JAK inhibitors), or hydroxychloroquine for SLE. The specific agent and dose are tailored to your presentation and clinical profile.
How long does treatment for Scleroderma (Systemic Sclerosis) last?+
Some conditions require short-term treatment (acute infections, self-limiting disorders). Many chronic conditions require indefinite treatment to maintain disease control and prevent relapse.
What happens if Scleroderma (Systemic Sclerosis) is not treated?+
Untreated Scleroderma (Systemic Sclerosis) can progress, increasing the risk of complications and organ damage. Early treatment generally leads to better outcomes and reduced long-term burden.
Our AI Symptom Checker analyzes your symptoms and suggests possible conditions based on clinical guidelines.
Start Free Analysis →